Old Dominion Freight Line Inc
Change company Symbol lookup
Select an option...
ODFL Old Dominion Freight Line Inc
NWFFX American Funds New World Fund® Class F-1
CARS Cars.com Inc
AHT Ashford Hospitality Trust Inc
AHII Fyolo Technology Corp
AHH-A Armada Hoffler Properties Inc
AHH Armada Hoffler Properties Inc
AHFD Active Health Foods Inc
AGSO AgriSolar Solutions Inc

Industrials : Road & Rail | Mid Cap Growth
Company profile

Old Dominion Freight Line, Inc. is a union-free motor carrier providing regional, inter-regional and national less-than-truckload (LTL) services. The Company's LTL services include ground and air expedited transportation for time-sensitive shipments, consumer household pickup and delivery and freight delivery services throughout North America. In addition to its LTL services, the Company offers a range of other value-added services that include container drayage, truckload brokerage, supply chain consulting and warehousing. As of December 31, 2016, the Company operated 226 service center locations, of which it owned 182 and leased 44. As of December 31, 2016, its network included 10 breakbulk facilities located in Rialto, California; Atlanta, Georgia; Columbus, Ohio; Indianapolis, Indiana; Greensboro, North Carolina; Harrisburg, Pennsylvania; Memphis and Morristown, Tennessee; Dallas, Texas, and Salt Lake City, Utah. As of December 31, 2016, the Company owned 7,994 tractors.

Closing Price
Day's Change
-6.43 (-3.38%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Regeneron shares gain as the company launches Phase 3 trial for COVID-19 antibody treatment

7:26 am ET July 6, 2020 (MarketWatch)

Shares of Regeneron Pharmaceuticals Inc. (REGN) gained 4.6% in premarket trading on Monday after the drugmaker said it had begun a Phase 3 clinical trial testing an antibody cocktail to prevent COVID-19. The study will specifically focus on the cocktail's efficacy preventing disease in 2,000 people who have been exposed to the virus by a close contact, such as a roommate. The trial is being operated by the National Institute of Allergy and Infectious Diseases. (A separate Phase 2/3 trial for the same antibody cocktail is testing the experimental therapy as a treatment in 2,900 COVID-19 patients who are being treated in hospitals and ambulatory settings. That trial is being run in the U.S. and in other countries like Brazil and Mexico.) On Thursday, Regeneron and Sanofi (SAN.FR) had announced that a study evaluating their rheumatoid arthritis treatment Kevzara had failed to meet a Phase 3 trial's primary or secondary endpoint (http://www.marketwatch.com/story/regeneron-sanofi-halt-trial-for-experimental-coronavirus-drug-shares-fall-2020-07-02)s in a study testing the drug as a COVID-19 treatment; that announcement sent down Regeneron's shares in after-hours trading. Regeneron's stock is up 65.7% year-to-date, while the S&P 500 is down 3.1%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 06, 2020 07:26 ET (11:26 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.